Intraoperative intraperitoneal administration of CDDP against gastric cancer with peritoneal dissemination

• Published in: Gan to kagaku ryoho Vol. 17; no. 2; p. 233
• Main Authors: Kano, T, Kawami, H, Kohdono, S, Oka, N, Inokuchi, K
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.02.1990
• Subjects: Adult; Aged; Ascitic Fluid - drug therapy; Cisplatin - administration & dosage; Cisplatin - therapeutic use; Female; Gastrectomy; Humans; Intraoperative Care; Male; Middle Aged; Mitomycin; Mitomycins - administration & dosage; Peritoneal Cavity; Picibanil - administration & dosage; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - surgery; Survival Rate
• ISSN: 0385-0684

This study was undertaken in order to evaluate the effect of intraoperative intraperitoneal (i.p.) administration of CDDP on patients who underwent gastrectomy for gastric cancer with peritoneal dissemination, compared with MMC or OK-432 i.p. administration group and untreated group. The median survival time was 11 months in CDDP i.p. group (35 patients), 8 months in MMC or OK-432 Ip group (33 patients) and 7 months in untreated group (25 patients). 1- and 2-year survival rates were 30.4% and 12.1% for MMC or OK-432 i.p. group, and 28% and 8% for untreated group, while in CDDP i.p. group, the rates were higher at 46.4% and 14.7%, respectively (CDDP i.p. group vs. untreated group, p less than 0.05). In vitro chemosensitivity test by succinate dehydrogenase inhibition (SDI) test supported the clinical results. CDDP had higher sensitivities than MMC and ADM on poorly differentiated cases as well as peritoneal dissemination cases. Our results suggest that intraoperative i.p. administration of CDDP was useful for the treatment of gastric cancer with peritoneal dissemination.